

*US Patent and Trademark Office*

---

**Amneal Pharmaceuticals LLC  
and Par Pharmaceutical, Inc.,  
v.  
Jazz Pharmaceuticals, Inc.,**

**CONFIDENTIAL**

---

***Deposition of:*  
Robert Valuck, Ph.D., R.Ph. - Vol. 2  
October 9, 2015**

Page 223

UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE PATENT TRIAL AND APPEAL BOARD  
-----  
AMNEAL PHARMACEUTICALS LLC  
AND PAR PHARMACEUTICAL, INC.,  
  
Petitioners,  
  
v.  
JAZZ PHARMACEUTICALS, INC.,  
  
Patent Owner.  
  
Case IPR2015-00546  
Patent 7,765,106  
-----  
DEPOSITION OF  
Robert Valuck, Ph.D., R.Ph. - Volume 2  
October 9, 2015  
Greenwood Village, Colorado  
Lead: Eric Stops, Esquire  
Firm: Quinn Emanuel  
  
FINAL COPY - CONFIDENTIAL  
JANE ROSE REPORTING 1-800-825-3341

Page 224

APPEARANCES  
  
ATTORNEY FOR PETITIONER AMNEAL  
Matthew C. Ruedy, Esquire  
MADDOX EDWARDS, PLLC  
1900 K Street, NW - Suite 725  
Washington, DC 20006  
202-830-0779  
mruedy@meiplaw.com  
  
ATTORNEYS FOR PETITIONER PAR  
PHARMACEUTICAL, INC., AND THE  
WITNESS  
Aziz Burgy, Esquire  
Bradford C. Frese, Esquire  
ARENT FOX LLP  
1717 K Street, NW  
Washington, DC 20006-5344  
202-857-6000  
aziz.burgy@arentfox.com  
bradford.frese@arentfox.com

Page 225

ATTORNEYS FOR THE PATENT OWNER  
Eric Stops, Esquire  
Frank C. Calvosa, Esquire  
QUINN EMANUEL  
51 Madison Avenue, 22nd Floor  
New York, New York 10010  
212-849-7000  
ericstops@quinnemanuel.com  
frankcalvosa@quinnemanuel.com  
- and -  
John V. Biernacki, Esquire  
JONES DAY  
901 Lakeside Avenue  
Cleveland, Ohio 44114  
216-586-3939  
jvbiernacki@jonesday.com  
  
ALSO PRESENT  
David Silverstein, Par Pharmaceutical  
  
JANE ROSE REPORTING  
74 Fifth Avenue  
New York, New York 10011  
1-800-825-3341  
Margie Dauster, Court Reporter

Page 226

TABLE OF CONTENTS  
  
Witness:  
Robert Valuck, Ph.D., R.Ph. - Volume 2  
  
Examination  
By Mr. Burgy.....Page 227  
By Mr. Stops.....Page 314  
  
Begin Confidential Portion.....Page 232/Line 15  
End Confidential Portion.....Page 236/Line 2  
Phone Conference with Board.....Page 300 - 314  
  
Reporter Certificate.....Page 345  
  
Notice to Read and Sign.....Page 347  
  
Index of Exhibits.....Page 349

Page 227

1                   \*   \*   \*

2                   Greenwood Village, Colorado

3                   9:29 a.m.

4                   \*   \*   \*

5

6                   ROBERT VALUCK, Phd, RPh,

7                   having been previously sworn, was examined

8                   and testified as follows:

9                   EXAMINATION

10                  BY MR. BURGYP:

11                  **Q. Good morning, Dr. Valuck.**

12                  A. Good morning.

13                  **Q. Welcome back to day 2 of your deposition.**

14                  **As you know, my name is Aziz Burgy. I**

15 **represent Par Pharmaceutical, Inc., in this matter. And**

16 **I'm going to be questioning you on redirect on some of**

17 **the topics that counsel, Mr. Eric Stops, asked you about**

18 **yesterday.**

19                  **Do you understand that?**

20                  A. Yes.

21                  **Q. Okay. And you understand that you're still**

22 **under oath today?**

23                  A. Yes.

24                  **Q. Before we get started today, I wanted to ask**

25 **you whether you had any discussions with counsel between**

Page 228

1                   **yesterday's cross-examination and today's redirect**

2 **questioning by me about your testimony today.**

3                   A. No.

4                   **Q. And did you do anything to prepare for your**

5 **deposition testimony today?**

6                   A. No.

7                   **Q. Counsel yesterday asked you about your**

8 **declarations that you submitted in the IPR proceedings**

9 **that are related to the Jazz patents. Do you recall**

10 **that?**

11                  A. Yes.

12                  **Q. Okay. Do you have any corrections to make to**

13 **your declarations that you know of? And there are**

14 **several declarations from yesterday, so feel free to**

15 **take a look.**

16                  A. If you don't mind. There's one thing that I

17 believe is a typo. As we were looking at the '730

18 declaration yesterday, we were talking about --

19                  **Q. Can you tell me what page you're on?**

20                  A. Yes. I'm talking about page 40. There's an

21 instance in the claim chart that refers to the -- the

22 video and transcript. And I refer in the middle of that

23 claim chart the entry "Pharmacy staff receives faxed

24 prescription and enters information from it into a

25 computer" and make reference to the video at PAR1006,

Page 229

1                   V7, 0 to 16 seconds. There -- and I believe there may

2 be other instances -- there may be another one at page

3 34 similarly.

4                   The places I refer to that -- that particular

5 instance from the video, I believe it's -- should be

6 segment -- Video Segment 8 rather than Video Segment 7

7 that I was referring to.

8                   **Q. And how did you come about to learn that that**

9 **was an error in the citation?**

10                  A. In -- in reviewing the -- rewatching the video

11 for prep myself the last couple of weeks. I rewatched

12 the video and reread this. And the videos submitted to

13 the -- as far as the -- backing up the references are in

14 little pieces. And reviewing them, looked at Video 7,

15 and it wasn't -- wasn't what I expected to be for that

16 step. It was really Video Segment 8 that I'm really

17 referring to.

18                  So that's a typo in any instance. And those

19 are the two that I see from having -- looking back at

20 this yesterday. Those are the two that I noticed. If

21 there's other instances where I refer to that entry --

22 pharmacy staff receives and enters into a computer --

23 referring to Video Segment 7, any instance of that

24 should be 8. And I -- and those are the two that I know

25 of. But if there's others, it would be the same

Page 230

1                   correction.

2                   **Q. Okay. So just so the record is clear, if**

3 **you're citing PAR1006, V7 from time stamp 0 to 16**

4 **seconds, that citation should be changed to Video 8 for**

5 **all applicable citations for all your declarations?**

6                   A. Yes.

7                   **Q. Okay.**

8                   A. That's the only one that I -- that I noticed as

9 a -- as a correction for my declarations.

10                  **Q. Okay. Let's move on, Dr. Valuck.**

11                  **Counsel asked you yesterday whether you have**

12 **been paid for your work on the six IPR declarations that**

13 **are the subject of the deposition. Do you recall that?**

14                  A. Yes.

15                  **Q. You testified that you have not been**

16 **compensated for your work. Do you recall that?**

17                  A. Yes.

18                  **Q. And why have you not been compensated for your**

19 **work?**

20                  A. I just haven't submitted invoices yet.

21                  **Q. Are Par Pharmaceutical, Inc., and Amneal aware**

22 **that you have not submitted any invoices for your work**

23 **on the six IPR declarations?**

24                  MR. STOPS: Objection. Form.

25                  A. I made them aware this week when -- when we met

Page 231

1 in -- prior to the deposition I made them aware of that.  
2 **Q. (By Mr. Burgy) And why had you not -- why have**  
3 **you not submitted invoices yet?**  
4 A. I just hadn't gotten around to it yet.  
5 **Q. So the client should expect a pretty hefty bill**  
6 **from you at some point.**  
7 A. Yeah, I suppose that may -- may cause a little  
8 bit of angst for accounting maybe. But I just hadn't --  
9 I just hadn't done it yet and will be doing so.  
10 (Par Exhibit Numbers 1042, 1043, and 1044 were  
11 marked.)  
12 **Q. Dr. Valuck, I've handed you three documents**  
13 **that have been marked as Exhibits PAR 1042, 1043, and**  
14 **1044. Do you see that?**  
15 MR. STOPS: Which one is which?  
16 MR. BURG Y: Sorry. And I was just going to get  
17 to that.  
18 MR. STOPS: Sorry.  
19 **Q. (By Mr. Burgy) So Xyrem -- the document that**  
20 **has the Bates Number Xyrem IPR 1 through 4 is -- has**  
21 **been marked PAR 1042. And Xyrem IPR 5 through 8 has**  
22 **been marked PAR 1043. And Xyrem IPR 9 through 11 has**  
23 **been marked 1044.**  
24 **Can you please confirm that that is correct on**  
25 **the documents that you have before you.**

Page 232

1 A. Yes.  
2 **Q. Do you recognize these three documents,**  
3 **Dr. Valuck?**  
4 A. Yes, I do.  
5 **Q. And what are these three documents?**  
6 A. These are the retainer agreement letters  
7 between the law firm or firms and myself related to  
8 these six IPRs that I prepared in this matter.  
9 **Q. And if we could take the first one, PAR 1042.**  
10 **Do you see that?**  
11 A. Yes.  
12 MR. BURG Y: And just for the record, I'd like  
13 to designate this portion of the transcript as  
14 confidential under the protective order.  
15 (The following portion is designated  
16 confidential.)  
17 **Q. (By Mr. Burgy) Dr. Valuck, do you see in the**  
18 **first sentence it says Par Pharmaceutical, Inc., the**  
19 **retaining party, has authorized you to retain -- has**  
20 **authorized us to retain you to provide consulting and**  
21 **expert witness services to Arent Fox on behalf of the**  
22 **retaining party? Do you see that?**  
23 A. Yes.  
24 **Q. And so who are you retained by with respect to**  
25 **these IPRs?**

Page 233

1 A. By Par Pharmaceutical, Inc.  
2 **Q. Okay. And with respect to PAR 1042, you**  
3 **testified that these are the engagement letters that**  
4 **encompass your work regarding the IPRs in this case?**  
5 A. Yes.  
6 **Q. And is this document -- this engagement letter**  
7 **at PAR 1042 specific to any of the specific Jazz**  
8 **patents?**  
9 A. Yes.  
10 **Q. Which? And which patents are those?**  
11 A. This is specific to the '059 patent and the  
12 '988 patent.  
13 **Q. Okay. Let's move on to the next document,**  
14 **which is PAR 1043. Are you there, sir?**  
15 A. Yes.  
16 **Q. And briefly, what is this document?**  
17 A. This, similarly, is another retainer agreement  
18 letter between law firms and myself related to some of  
19 the IPR work that I've done here.  
20 **Q. And who are the retaining parties?**  
21 A. Here it's Amneal Pharmaceuticals, LLC, and Par  
22 Pharmaceutical, Inc. Hang on. There's a typo. This  
23 one --  
24 **Q. Where is that?**  
25 A. The first line. It says "Amneal

Page 234

1 Pharmaceuticals, LLC (Amneal) and Par Pharmaceutical  
2 (Par)," which should be "Par Pharmaceutical, Inc.  
3 (Par)" --  
4 **Q. Oh, okay. Thank you.**  
5 A. -- "collectively have authorized" and such.  
6 **Q. Okay. And so Amneal and Par are the retaining**  
7 **parties; is that correct?**  
8 A. Yes.  
9 **Q. And this engagement letter pertains to which**  
10 **Jazz patent?**  
11 A. This letter specifically pertains to the '730  
12 patent.  
13 **Q. All right. And this letter encompasses your**  
14 **work with respect to the IPR declarations that you've**  
15 **submitted with respect to the '730 patent; is that**  
16 **correct?**  
17 MR. STOPS: Objection. Form.  
18 A. Yes.  
19 **Q. (By Mr. Burgy) If we can move on to the last**  
20 **document, which is PAR 1044. Do you see that?**  
21 A. Yes.  
22 **Q. And what is this document?**  
23 A. Similarly, this is a retainer agreement letter  
24 between law firms and myself related to some of the IPR  
25 declarations that I've prepared for this matter.

Page 235

1 **Q. And who are the retaining parties?**  
2 A. On this letter, the retaining parties are  
3 Amneal Pharmaceuticals (Amneal) and Par Pharmaceutical,  
4 Inc. -- same -- sorry -- same typo --  
5 **Q. Okay.**  
6 A. -- as on the last letter. The first one should  
7 be Par Pharmaceutical, Inc., in the first line. And  
8 between Sterne, Kessler, Goldstein & Fox -- Locke Lord  
9 is a typo as well. Locke Lord is not involved in this  
10 one.  
11 **Q. Okay.**  
12 A. It's just Sterne, Kessler, Goldstein & Fox and  
13 Arent Fox.  
14 **Q. And what patents does this engagement letter**  
15 **refer to?**  
16 A. And this letter refers to the '182 patent, the  
17 '106 patent, and the '107 patent.  
18 **Q. And does this engagement letter encompass your**  
19 **work with respect to the IPR declarations that you've**  
20 **submitted with respect to the '182, '106, and '107**  
21 **patents?**  
22 MR. STOPS: Objection. Form.  
23 A. Yes, it does.  
24 **Q. (By Mr. Burgy) Okay. You can put that aside.**  
25 MR. BURG: And we can go off the confidential

Page 236

1 record.  
2 (End of confidential portion.)  
3 **Q. (By Mr. Burgy) Dr. Valuck, yesterday you --**  
4 **strike that.**  
5 **Yesterday counsel asked you about a person of**  
6 **ordinary skill in the art. Do you recall that?**  
7 A. Yes.  
8 **Q. And specifically counsel asked you about the**  
9 **qualifications related to a person of ordinary skill in**  
10 **the art?**  
11 A. Yes.  
12 **Q. And specifically you testified that a PharmD**  
13 **was the only doctor of pharmacy degree, I believe is**  
14 **what you said. Do you recall that?**  
15 A. Yes.  
16 **Q. What educational background do you have in**  
17 **pharmacy?**  
18 A. I have a bachelor's degree in pharmacy, a  
19 master's degree in pharmacy, and a PhD degree in  
20 pharmacy.  
21 **Q. How is a PhD in pharmacy different from a**  
22 **PharmD, if any?**  
23 A. They're -- they're both doctorate degrees, but  
24 it -- the doctor of pharmacy degree is a very specific  
25 degree. The PharmD is called doctor of pharmacy. The

Page 237

1 PhD degree is doctor of philosophy in pharmacy. It's  
2 also in the field. It's an advanced degree beyond  
3 the -- what we call the entry-level practice degree.  
4 And the entry-level practice degrees are either  
5 a bachelor's degree in pharmacy or a PharmD degree.  
6 Those two degrees -- one of them is a requirement for  
7 practice and licensure. Master's and PhD degrees are  
8 additional training in research and different aspects of  
9 pharmacy, specific aspects.  
10 A PharmD degree is advanced training in certain  
11 aspects, clinical aspects. Each is advanced training  
12 beyond the entry-level training. It's a very -- it's a  
13 small thing. But doctor of pharmacy versus doctorate in  
14 pharmacy, there are slight differences but both of those  
15 exist. So it can be confusing to someone who doesn't  
16 know those various degrees exist.  
17 **Q. Do you consider yourself to be a person of**  
18 **ordinary skill in the art with respect to this case?**  
19 A. Yes.  
20 **Q. How so?**  
21 A. I have a -- what I believe a POSA would have,  
22 is one of the entry-level practice degrees in pharmacy  
23 as -- one version. So I have a bachelor's degree in  
24 pharmacy. I have three to five years of work  
25 experience. I have experience in a variety of practice

Page 238

1 settings. So I consider myself a POSA.  
2 **Q. I'd like to turn to your declaration with**  
3 **respect to the '730 patent. You have a pile of exhibits**  
4 **that we used yesterday. If you could pull that up.**  
5 A. Yes.  
6 **Q. Do you have that?**  
7 A. Yes.  
8 **Q. Do you recall that Jazz's counsel asked you**  
9 **about your expertise in this case yesterday? Do you**  
10 **recall that?**  
11 A. Yes.  
12 **Q. And, specifically, if you would turn to page 6**  
13 **of your declaration at paragraph 9. Do you see that?**  
14 A. Yes.  
15 **Q. I'm at the second sentence at paragraph 9 where**  
16 **you state, "I am an expert in the fields of drug safety,**  
17 **drug abuse prevention, and prescription drug**  
18 **distribution."**  
19 **Do you see that?**  
20 A. Yes.  
21 **Q. If we could take each of these in turn. What**  
22 **is the basis of your expertise in drug safety?**  
23 A. Well, it comes from a variety of different  
24 areas. I have specific education and training. I have  
25 work experience. I have research experience. I have

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.